



# Jagsonpal Pharmaceuticals Ltd

**Corporate Office:** Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,  
Sector-18, Gurugram -122015, Haryana (India)

**Ph.:** +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com

**CIN. :** L74899DL1978PLC009181



March 12, 2026

The Department of Corporate Services- Listing <b>BSE Ltd,</b> Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 <b>Scrip Code: 507789</b>	The Department of Corporate Services- Listing <b>National Stock Exchange of India Ltd</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 <b>Symbol: JAGSNPHARM</b>
---	--

**Subject: Press Release on announcement of Buy- Back of Equity shares of the Company**

Dear Sir/ Madam,

Please find enclosed herewith a copy of the Press Release relating to announcement of Buy- Back of Equity shares of the Company.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For **Jagsonpal Pharmaceuticals Limited**

**Pratham Rawal**

**Company Secretary & Compliance Officer**



## Jagsonpal announces Buyback of equity shares

- Buyback price of ₹250, a premium of 40% to current market price
- Buyback of up to 16 lakh equity shares for a total consideration of ₹ 40 crores
- Promoters not to participate in the Buyback

Gurugram, March 12, 2026; The Board of Directors of Jagsonpal Pharmaceuticals Limited at its meeting today approved a proposal to buyback up to 16,00,000 fully paid-up equity shares of the company through Tender Offer method, subject to shareholders approval. This represents 2.4% of the total equity shares of the Company and 7.3% of the non-promoter shareholding of the company.

The proposed buyback will be undertaken for an aggregate amount not exceeding ₹ 40 crores, representing ~18.4% of the company's total paid-up equity share capital and free reserves based on the latest audited financial statements as of 31 March 2025

### **Rationale for the proposed Buyback:**

- a. The Company operates with an asset-light business model, which requires insignificant capital to scale-up, other than for inorganic initiatives
- b. The Company has added over ₹ 142 crores of free cash between FY22 to FY25, despite increased dividends and ₹ 95 crores deployed for acquisition
- c. As on December 31, 2025, the Company has free cash of ₹ 176 Crores
- d. The Company added ₹ 30 crores of free cash during the 9M period ended December 31, 2025 and also paid out a dividend of ₹ 17 crores
- e. With the recent regulatory changes allowing M&A funding by banks, the Company intends to use blend of equity and debt for any inorganic growth opportunity
- f. The proposed buyback shall lead to ~400 bps improvement in ROCE

The promoters of the Company shall not be participating in the buy-back. The promoter shareholding shall increase from current 67.2% to 68.9% post completion of buyback, assuming buyback of 16 lakh equity shares.

Manish Gupta, Managing Director, Jagsonpal Pharmaceuticals Limited, said:

“The proposed buyback demonstrates the company’s continued commitment to enhancing shareholder value and optimizing its capital structure. This is intended to reward shareholders and is expected to improve key metrics including earnings per share and return on capital employed, while maintaining sufficient capital to support the company’s ongoing growth initiatives including exploring inorganic initiatives.

#### **ABOUT JAGSONPAL PHARMACEUTICALS LIMITED**

Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company with a proven track record of over four decades in the Indian pharmaceutical market.

The Company has a robust portfolio of drugs focusing on Gynaecology, Orthopaedics, Dermatology and Child-care segments. Over the years, the Company has successfully built multiple brands that today hold market-leading positions in their respective segments. It has created a strong niche for itself with 20+ brands amongst Top 5 brands in the molecule category, extensive pan-India presence and an experienced sales team of over 1000 professionals.

The company is listed on the National Stock Exchange Limited (JAGSNPHARM) and Bombay Stock Exchange (Scrip code: 507789) and is headquartered in Delhi.

For more information, please visit: [www.jagsonpal.com](http://www.jagsonpal.com)

<a href="#">Company contact</a>	<a href="#">Investor Relations Team</a>
Email: <a href="mailto:cs@jagsonpal.com">cs@jagsonpal.com</a> , Tel: +91 124 4406710  Jagsonpal Pharmaceuticals Limited CIN: L74899DL1978PLC009181 Registered Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 Corporate Office: Nimai Tower, 3 <sup>rd</sup> floor, Udyog Vihar, Gurugram, Haryana – 122015	Soumya Chhajer Email- <a href="mailto:soumya@goindiaadvisors.com">soumya@goindiaadvisors.com</a> Mobile: +91-8619707750